Ung thư thực quản và khớp thực quản-dạ dày, Phiên bản 2.2019, Hướng dẫn thực hành lâm sàng NCCN trong ung thư học

Bang, 2009, Pathological features of advanced gastric cancer (GC): relationship to human epidermal growth factor receptor 2 (HER2) positivity in the global screening programme of the ToGA trial [abstract], J Clin Oncol, 27, Abstract 4556, 10.1200/jco.2009.27.15_suppl.4556

Conroy, 2014, Definitive chemoradiotherapy with FOLFOX versus fluorouracil and cisplatin in patients with oesophageal cancer (PRODIGE5/ACCORD17): final results of a randomised, phase 2/3 trial, Lancet Oncol, 15, 305, 10.1016/S1470-2045(14)70028-2

Albertsson, 2007, Phase II studies on docetaxel alone every third week, or weekly in combination with gemcitabine in patients with primary locally advanced, metastatic, or recurrent esophageal cancer, Med Oncol, 24, 407, 10.1007/s12032-007-0028-6

Lagergren, 2000, The role of tobacco, snuff and alcohol use in the aetiology of cancer of the oesophagus and gastric cardia, Int J Cancer, 85, 340, 10.1002/(SICI)1097-0215(20000201)85:3<340::AID-IJC8>3.0.CO;2-N

Cunningham, 2008, Capecitabine and oxaliplatin for advanced esophagogastric cancer, N Engl J Med, 358, 36, 10.1056/NEJMoa073149

Sudo, 2014, Importance of surveillance and success of salvage strategies after definitive chemoradiation in patients with esophageal cancer, J Clin Oncol, 32, 3400, 10.1200/JCO.2014.56.7156

Ford, 2014, Docetaxel versus active symptom control for refractory oesophagogastric adenocarcinoma (COUGAR-02): an open-label, phase 3 randomised controlled trial, Lancet Oncol, 15, 78, 10.1016/S1470-2045(13)70549-7

Li, 2010, Definitive concomitant chemoradiotherapy with docetaxel and cisplatin in squamous esophageal carcinoma, Dis Esophagus, 23, 253, 10.1111/j.1442-2050.2009.01003.x

Li, 2010, Definitive concomitant chemoradiotherapy with docetaxel and cisplatin in squamous esophageal carcinoma, Dis Esophagus, 23, 253, 10.1111/j.1442-2050.2009.01003.x

Siegel, 2019, Cancer statistics, 2019, CA Cancer J Clin, 69, 7, 10.3322/caac.21551

Engel, 2003, Population attributable risks of esophageal and gastric cancers, J Natl Cancer Inst, 95, 1404, 10.1093/jnci/djg047

Conroy, 2014, Definitive chemoradiotherapy with FOLFOX versus fluorouracil and cisplatin in patients with oesophageal cancer (PRODIGE5/ACCORD17): final results of a randomised, phase 2/3 trial, Lancet Oncol, 15, 305, 10.1016/S1470-2045(14)70028-2

Smalley, 2012, Updated analysis of SWOG-directed intergroup study 0116: a phase III trial of adjuvant radiochemotherapy versus observation after curative gastric cancer resection, J Clin Oncol, 30, 2327, 10.1200/JCO.2011.36.7136

CatenacciDV, 2017, KEYNOTE cohort safety and efficacy of pembrolizumab monotherapy for first - line treatment of patients pts with positive advanced gastric / gastroesophageal cancer suppl, Ann Oncol, 28, 059

Shapiro, 2015, Neoadjuvant chemoradiotherapy plus surgery versus surgery alone for oesophageal or junctional cancer (CROSS): long-term results of a randomised controlled trial, Lancet Oncol, 16, 1090, 10.1016/S1470-2045(15)00040-6

Torre, 2015, Global cancer statistics, 2012, CA Cancer J Clin, 65, 87, 10.3322/caac.21262

Sym, 2013, A randomized phase II study of biweekly irinotecan monotherapy or a combination of irinotecan plus 5-fluorouracil/leucovorin (mFOLFIRI) in patients with metastatic gastric adenocarcinoma refractory to or progressive after first-line chemotherapy, Cancer Chemother Pharmacol, 71, 481, 10.1007/s00280-012-2027-3

Bando, 2016, A multicenter phase II study of TAS-102 monotherapy in patients with pre-treated advanced gastric cancer (EPOC1201), Eur J Cancer, 62, 46, 10.1016/j.ejca.2016.04.009

Alderson, 2017, Neoadjuvant cisplatin and fluorouracil versus epirubicin, cisplatin, and capecitabine followed by resection in patients with oesophageal adenocarcinoma (UK MRC OE05): an open-label, randomised phase 3 trial, Lancet Oncol, 18, 1249, 10.1016/S1470-2045(17)30447-3

Al-Batran, 2008, Phase III trial in metastatic gastroesophageal adenocarcinoma with fluorouracil, leucovorin plus either oxaliplatin or cisplatin: a study of the Arbeitsgemeinschaft Internistische Onkologie, J Clin Oncol, 26, 1435, 10.1200/JCO.2007.13.9378

Kim, 2012, A randomized phase II trial of S-1-oxaliplatin versus capecitabine-oxaliplatin in advanced gastric cancer, Eur J Cancer, 48, 518, 10.1016/j.ejca.2011.12.017

Petrasch, 1998, Chemotherapy with cisplatin and paclitaxel in patients with locally advanced, recurrent or metastatic oesophageal cancer, Br J Cancer, 78, 511, 10.1038/bjc.1998.524

Noh, 2014, Adjuvant capecitabine plus oxaliplatin for gastric cancer after D2 gastrectomy (CLASSIC): 5-year follow-up of an open-label, randomised phase 3 trial, Lancet Oncol, 15, 1389, 10.1016/S1470-2045(14)70473-5

Rusch, 2004, Are cancers of the esophagus, gastroesophageal junction, and cardia one disease, two, or several?, Semin Oncol, 31, 444, 10.1053/j.seminoncol.2004.04.023

Bascoul-Mollevi, 2017, Health-related quality of life results from the PRODIGE 5/ACCORD 17 randomised trial of FOLFOX versus fluorouracil-cisplatin regimen in oesophageal cancer, Eur J Cancer, 84, 239, 10.1016/j.ejca.2017.07.038

Boonstra, 2011, Chemotherapy followed by surgery versus surgery alone in patients with resectable oesophageal squamous cell carcinoma: long-term results of a randomized controlled trial, BMC Cancer, 11, 181, 10.1186/1471-2407-11-181

Tabernero, 2017, Exposure-response analyses of ramucirumab from two randomized, phase III trials of second-line treatment of advanced gastric or gastroesophageal junction cancer, Mol Cancer Ther, 16, 2215, 10.1158/1535-7163.MCT-16-0895

Steyerberg, 2006, Surgical mortality in patients with esophageal cancer: development and validation of a simple risk score, J Clin Oncol, 24, 4277, 10.1200/JCO.2005.05.0658

Shah, Efficacy and safety of pembrolizumab for heavily pretreated patients with advanced, metastatic adenocarcinoma or squamous cell carcinoma of the esophagus: the phase 2 KEYNOTE-180 study [published online December 20, 2018], JAMA Oncol.

Siewert, 2007, Are squamous and adenocarcinomas of the esophagus the same disease?, Semin Radiat Oncol, 17, 38, 10.1016/j.semradonc.2006.09.007

Ajani, 2005, Phase II multi-institutional randomized trial of docetaxel plus cisplatin with or without fluorouracil in patients with untreated, advanced gastric, or gastroesophageal adenocarcinoma, J Clin Oncol, 23, 5660, 10.1200/JCO.2005.17.376

Soularue, 2015, Efficacy and safety of trastuzumab in combination with oxaliplatin and fluorouracil-based chemotherapy for patients with HER2-positive metastatic gastric and gastro-oesophageal junction adenocarcinoma patients: a retrospective study, Bull Cancer, 102, 324, 10.1016/j.bulcan.2014.08.001

Shitara, 2018, Pembrolizumab versus paclitaxel for previously treated, advanced gastric or gastro-oesophageal junction cancer (KEYNOTE-061): a randomised, open-label, controlled, phase 3 trial, Lancet, 392, 123, 10.1016/S0140-6736(18)31257-1

Groth, 2010, Determination of the minimum number of lymph nodes to examine to maximize survival in patients with esophageal carcinoma: data from the Surveillance Epidemiology and End Results database, J Thorac Cardiovasc Surg, 139, 612, 10.1016/j.jtcvs.2009.07.017

Ilson, 2007, Paclitaxel given by a weekly 1-h infusion in advanced esophageal cancer, Ann Oncol, 18, 898, 10.1093/annonc/mdm004

Murphy, 2006, Comparison of the microsatellite instability analysis system and the Bethesda panel for the determination of microsatellite instability in colorectal cancers, J Mol Diagn, 8, 305, 10.2353/jmoldx.2006.050092

Fiorica, 2004, Preoperative chemoradiotherapy for oesophageal cancer: a systematic review and meta-analysis, Gut, 53, 925, 10.1136/gut.2003.025080

Hong, 2004, A phase II trial of capecitabine in previously untreated patients with advanced and/or metastatic gastric cancer, Ann Oncol, 15, 1344, 10.1093/annonc/mdh343

Sharma, 2009, A single institution experience with neoadjuvant chemoradiation (CRT) with irinotecan (I) and cisplatin (C) in locally advanced esophageal carcinoma (LAEC) [abstract], J Clin Oncol, 27, e15619, 10.1200/jco.2009.27.15_suppl.e15619

Cunningham, 2006, Perioperative chemotherapy versus surgery alone for resectable gastroesophageal cancer, N Engl J Med, 355, 11, 10.1056/NEJMoa055531

Murphy, 2006, Comparison of the microsatellite instability analysis system and the Bethesda panel for the determination of microsatellite instability in colorectal cancers, J Mol Diagn, 8, 305, 10.2353/jmoldx.2006.050092

Le, 2017, Mismatch repair deficiency predicts response of solid tumors to PD-1 blockade, Science, 357, 409, 10.1126/science.aan6733

Fiorica, 2004, Preoperative chemoradiotherapy for oesophageal cancer: a systematic review and meta-analysis, Gut, 53, 925, 10.1136/gut.2003.025080

Cunningham, 2006, Perioperative chemotherapy versus surgery alone for resectable gastroesophageal cancer, N Engl J Med, 355, 11, 10.1056/NEJMoa055531

van Hagen, 2012, Preoperative chemoradiotherapy for esophageal or junctional cancer, N Engl J Med, 366, 2074, 10.1056/NEJMoa1112088

Minsky, 2002, INT 0123 (Radiation Therapy Oncology Group 94-05) phase III trial of combined-modality therapy for esophageal cancer: high-dose versus standard-dose radiation therapy, J Clin Oncol, 20, 1167, 10.1200/JCO.2002.20.5.1167

Shah, 2015, Randomized multicenter phase II study of modified docetaxel, cisplatin, and fluorouracil (DCF) versus DCF plus growth factor support in patients with metastatic gastric adenocarcinoma: a study of the US Gastric Cancer Consortium, J Clin Oncol, 33, 3874, 10.1200/JCO.2015.60.7465

Ruppert, 2010, Cisplatin/irinotecan versus carboplatin/paclitaxel as definitive chemoradiotherapy for locoregionally advanced esophageal cancer, Am J Clin Oncol, 33, 346, 10.1097/COC.0b013e3181aaca26

Coccolini, 2018, Neoadjuvant chemotherapy in advanced gastric and esophago-gastric cancer. Meta-analysis of randomized trials, Int J Surg, 51, 120, 10.1016/j.ijsu.2018.01.008

Ajani, 2006, Phase II trial of preoperative chemoradiation in patients with localized gastric adenocarcinoma (RTOG 9904): quality of combined modality therapy and pathologic response, J Clin Oncol, 24, 3953, 10.1200/JCO.2006.06.4840

Van Cutsem, 2015, Docetaxel plus oxaliplatin with or without fluorouracil or capecitabine in metastatic or locally recurrent gastric cancer: a randomized phase II study, Ann Oncol, 26, 149, 10.1093/annonc/mdu496

Shah, Efficacy and safety of pembrolizumab for heavily pretreated patients with advanced, metastatic adenocarcinoma or squamous cell carcinoma of the esophagus: the phase 2 KEYNOTE-180 study [published online December 20, 2018], JAMA Oncol.

Al-Batran, 2017, Management of locally advanced gastroesophageal cancer: still a multidisciplinary global challenge?, Hematol Oncol Clin North Am, 31, 441, 10.1016/j.hoc.2017.01.004

Siegel, 2019, Cancer statistics, 2019, CA Cancer J Clin, 69, 7, 10.3322/caac.21551

Zhao, 2018, Neoadjuvant chemotherapy versus neoadjuvant chemoradiotherapy for cancer of the esophagus or the gastroesophageal junction: A meta-analysis based on clinical trials, PLoS One, 13, e0202185, 10.1371/journal.pone.0202185

Ilson, 2004, Phase II trial of weekly irinotecan/cisplatin in advanced esophageal cancer, Oncology (Williston Park), 18, 22

Kim, 2009, Multimodality assessment of esophageal cancer: preoperative staging and monitoring of response to therapy, Radiographics, 29, 403, 10.1148/rg.292085106

Doi, 2018, Safety and antitumor activity of the anti–programmed death-1 antibody pembrolizumab in patients with advanced esophageal carcinoma, J Clin Oncol, 36, 61, 10.1200/JCO.2017.74.9846

Ajani, 2005, Phase II multi-institutional randomized trial of docetaxel plus cisplatin with or without fluorouracil in patients with untreated, advanced gastric, or gastroesophageal adenocarcinoma, J Clin Oncol, 23, 5660, 10.1200/JCO.2005.17.376

Noordman, 2018, Effect of neoadjuvant chemoradiotherapy on health-related quality of life in esophageal or junctional cancer: results from the randomized CROSS trial, J Clin Oncol, 36, 268, 10.1200/JCO.2017.73.7718

Ryan, 2011, Obesity, metabolic syndrome and esophageal adenocarcinoma: epidemiology, etiology and new targets, Cancer Epidemiol, 35, 309, 10.1016/j.canep.2011.03.001

Freedman, 2007, A prospective study of tobacco, alcohol, and the risk of esophageal and gastric cancer subtypes, Am J Epidemiol, 165, 1424, 10.1093/aje/kwm051

CatenacciDV, 2017, KEYNOTE cohort safety and efficacy of pembrolizumab monotherapy for first - line treatment of patients pts with positive advanced gastric / gastroesophageal cancer suppl, Ann Oncol, 28, 059

Gravalos, 2008, HER2 in gastric cancer: a new prognostic factor and a novel therapeutic target, Ann Oncol, 19, 1523, 10.1093/annonc/mdn169

Noordman, 2018, Effect of neoadjuvant chemoradiotherapy on health-related quality of life in esophageal or junctional cancer: results from the randomized CROSS trial, J Clin Oncol, 36, 268, 10.1200/JCO.2017.73.7718

Fuchs, 2003, Phase III comparison of two irinotecan dosing regimens in second-line therapy of metastatic colorectal cancer, J Clin Oncol, 21, 807, 10.1200/JCO.2003.08.058

de Graaf, 2007, The role of staging laparoscopy in oesophagogastric cancers, Eur J Surg Oncol, 33, 988, 10.1016/j.ejso.2007.01.007

Maugeri-Saccà, 2013, FOLFIRI as a second-line therapy in patients with docetaxel-pretreated gastric cancer: a historical cohort, J Exp Clin Cancer Res, 32, 67, 10.1186/1756-9966-32-67

Doi, 2018, Safety and antitumor activity of the anti–programmed death-1 antibody pembrolizumab in patients with advanced esophageal carcinoma, J Clin Oncol, 36, 61, 10.1200/JCO.2017.74.9846

Soularue, 2015, Efficacy and safety of trastuzumab in combination with oxaliplatin and fluorouracil-based chemotherapy for patients with HER2-positive metastatic gastric and gastro-oesophageal junction adenocarcinoma patients: a retrospective study, Bull Cancer, 102, 324, 10.1016/j.bulcan.2014.08.001

Tanner, 2005, Amplification of HER-2 in gastric carcinoma: association with Topoisomerase IIalpha gene amplification, intestinal type, poor prognosis and sensitivity to trastuzumab, Ann Oncol, 16, 273, 10.1093/annonc/mdi064

Rüschoff, 2010, HER2 diagnostics in gastric cancer-guideline validation and development of standardized immunohistochemical testing, Virchows Arch, 457, 299, 10.1007/s00428-010-0952-2

Fuchs, 2014, Ramucirumab monotherapy for previously treated advanced gastric or gastro-oesophageal junction adenocarcinoma (REGARD): an international, randomised, multicentre, placebo-controlled, phase 3 trial, Lancet, 383, 31, 10.1016/S0140-6736(13)61719-5

Lustberg, 2010, Phase II randomized study of two regimens of sequentially administered mitomycin C and irinotecan in patients with unresectable esophageal and gastroesophageal adenocarcinoma, J Thorac Oncol, 5, 713, 10.1097/JTO.0b013e3181d7776d

Muro, 2016, Pembrolizumab for patients with PD-L1-positive advanced gastric cancer (KEYNOTE-012): a multicentre, open-label, phase 1b trial, Lancet Oncol, 17, 717, 10.1016/S1470-2045(16)00175-3

Bando, 2016, A multicenter phase II study of TAS-102 monotherapy in patients with pre-treated advanced gastric cancer (EPOC1201), Eur J Cancer, 62, 46, 10.1016/j.ejca.2016.04.009

Rice, 2017, Cancer of the esophagus and esophagogastric junction-major changes in the American Joint Committee on Cancer eighth edition cancer staging manual, CA Cancer J Clin, 67, 304

Tepper, 2008, Phase III trial of trimodality therapy with cisplatin, fluorouracil, radiotherapy, and surgery compared with surgery alone for esophageal cancer: CALGB 9781, J Clin Oncol, 26, 1086, 10.1200/JCO.2007.12.9593

Sudo, 2013, Locoregional failure rate after preoperative chemoradiation of esophageal adenocarcinoma and the outcomes of salvage strategies, J Clin Oncol, 31, 4306, 10.1200/JCO.2013.51.7250

Bang, 2017, KEYNOTE-059 cohort 2: safety and efficacy of pembrolizumab (pembro) plus 5-fluorouracil (5-FU) and cisplatin for first-line (1L) treatment of advanced gastric cancer, J Clin Oncol, 35, 4012, 10.1200/JCO.2017.35.15_suppl.4012

Taketa, 2014, Post-chemoradiation surgical pathology stage can customize the surveillance strategy in patients with esophageal adenocarcinoma, J Natl Compr Canc Netw, 12, 1139, 10.6004/jnccn.2014.0111

Tirumani, 2015, Esophageal carcinoma: current concepts in the role of imaging in staging and management, Can Assoc Radiol J, 66, 130, 10.1016/j.carj.2014.08.006

Sumpter, 2005, Report of two protocol planned interim analyses in a randomised multicentre phase III study comparing capecitabine with fluorouracil and oxaliplatin with cisplatin in patients with advanced oesophagogastric cancer receiving ECF, Br J Cancer, 92, 1976, 10.1038/sj.bjc.6602572

Ross, 2002, Prospective randomized trial comparing mitomycin, cisplatin, and protracted venous-infusion fluorouracil (PVI 5-FU) with epirubicin, cisplatin, and PVI 5-FU in advanced esophagogastric cancer, J Clin Oncol, 20, 1996, 10.1200/JCO.2002.08.105

Kato, 2019, KEYNOTE-590: Phase III study of first-line chemotherapy with or without pembrolizumab for advanced esophageal cancer, Future Oncol, 15, 1057, 10.2217/fon-2018-0609

Fuchs, 2003, Phase III comparison of two irinotecan dosing regimens in second-line therapy of metastatic colorectal cancer, J Clin Oncol, 21, 807, 10.1200/JCO.2003.08.058

Sharma, 2009, A single institution experience with neoadjuvant chemoradiation (CRT) with irinotecan (I) and cisplatin (C) in locally advanced esophageal carcinoma (LAEC) [abstract], J Clin Oncol, 27, e15619, 10.1200/jco.2009.27.15_suppl.e15619

Kleinberg, 2007, Chemoradiation in the management of esophageal cancer, J Clin Oncol, 25, 4110, 10.1200/JCO.2007.12.0881

BartleyAN, 2018, Template for reporting results of DNA mismatch repair testing in patients being considered for checkpoint inhibitor immunotherapy Illinois College of American Pathologists

Kofoed, 2012, Survival after adjuvant chemoradiotherapy or surgery alone in resectable adenocarcinoma at the gastro-esophageal junction, Scand J Surg, 101, 26, 10.1177/145749691210100106

Fuchs, 2019, Ramucirumab with cisplatin and fluoropyrimidine as first-line therapy in patients with metastatic gastric or junctional adenocarcinoma (RAINFALL): a double-blind, randomised, placebo-controlled, phase 3 trial, Lancet Oncol, 20, 420, 10.1016/S1470-2045(18)30791-5

Rüdiger Siewert, 2000, Adenocarcinoma of the esophagogastric junction: results of surgical therapy based on anatomical/topographic classification in 1,002 consecutive patients, Ann Surg, 232, 353, 10.1097/00000658-200009000-00007

Cunningham, 2008, Capecitabine and oxaliplatin for advanced esophagogastric cancer, N Engl J Med, 358, 36, 10.1056/NEJMoa073149

Ruppert, 2010, Cisplatin/irinotecan versus carboplatin/paclitaxel as definitive chemoradiotherapy for locoregionally advanced esophageal cancer, Am J Clin Oncol, 33, 346, 10.1097/COC.0b013e3181aaca26

Lustberg, 2010, Phase II randomized study of two regimens of sequentially administered mitomycin C and irinotecan in patients with unresectable esophageal and gastroesophageal adenocarcinoma, J Thorac Oncol, 5, 713, 10.1097/JTO.0b013e3181d7776d

Siewert, 2007, Are squamous and adenocarcinomas of the esophagus the same disease?, Semin Radiat Oncol, 17, 38, 10.1016/j.semradonc.2006.09.007

Ohtsu, 2003, Randomized phase III trial of fluorouracil alone versus fluorouracil plus cisplatin versus uracil and tegafur plus mitomycin in patients with unresectable, advanced gastric cancer: the Japan Clinical Oncology Group Study (JCOG9205), J Clin Oncol, 21, 54, 10.1200/JCO.2003.04.130

Nath, 2008, Peritoneal lavage cytology in patients with oesophagogastric adenocarcinoma, Br J Surg, 95, 721, 10.1002/bjs.6107

Iyer, 2004, Controversies in the multimodality management of locally advanced esophageal cancer: evidence-based review of surgery alone and combined-modality therapy, Ann Surg Oncol, 11, 665, 10.1245/ASO.2004.10.026

Wolff, 2009, Weekly high-dose 5-fluorouracil as a 24-h infusion and sodium folinic acid (AIO regimen) plus irinotecan in patients with locally advanced nonresectable and metastatic adenocarcinoma or squamous cell carcinoma of the oesophagus: a phase II trial, Anticancer Drugs, 20, 165, 10.1097/CAD.0b013e32831f8ec9

Urschel, 2003, A meta-analysis of randomized controlled trials that compared neoadjuvant chemoradiation and surgery to surgery alone for resectable esophageal cancer, Am J Surg, 185, 538, 10.1016/S0002-9610(03)00066-7

Park, 2008, Capecitabine in combination with oxaliplatin (XELOX) as a first-line therapy for advanced gastric cancer, Cancer Chemother Pharmacol, 61, 623, 10.1007/s00280-007-0515-7

Shitara, 2018, Trifluridine/tipiracil versus placebo in patients with heavily pretreated metastatic gastric cancer (TAGS): a randomised, double-blind, placebo-controlled, phase 3 trial, Lancet Oncol, 19, 1437, 10.1016/S1470-2045(18)30739-3

Lorenzen, 2009, Cetuximab plus cisplatin-5-fluorouracil versus cisplatin-5-fluorouracil alone in first-line metastatic squamous cell carcinoma of the esophagus: a randomized phase II study of the Arbeitsgemeinschaft Internistische Onkologie, Ann Oncol, 20, 1667, 10.1093/annonc/mdp069

Ilson, 2000, A phase II trial of paclitaxel and cisplatin in patients with advanced carcinoma of the esophagus, Cancer J, 6, 316

Steyerberg, 2006, Surgical mortality in patients with esophageal cancer: development and validation of a simple risk score, J Clin Oncol, 24, 4277, 10.1200/JCO.2005.05.0658

Iyer, 2004, Controversies in the multimodality management of locally advanced esophageal cancer: evidence-based review of surgery alone and combined-modality therapy, Ann Surg Oncol, 11, 665, 10.1245/ASO.2004.10.026

Sym, 2013, A randomized phase II study of biweekly irinotecan monotherapy or a combination of irinotecan plus 5-fluorouracil/leucovorin (mFOLFIRI) in patients with metastatic gastric adenocarcinoma refractory to or progressive after first-line chemotherapy, Cancer Chemother Pharmacol, 71, 481, 10.1007/s00280-012-2027-3

Torre, 2016, Global cancer incidence and mortality rates and trends–an update, Cancer Epidemiol Biomarkers Prev, 25, 16, 10.1158/1055-9965.EPI-15-0578

Herceptin, 2010, Administration approves trastuzumab Available at http wayback archive it org http www fda gov AboutFDA CentersOffices OfficeofMedicalProductsandTobacco CDER ucm htm Accessed, Food Drug, 21, 7993

Bang, 2012, Adjuvant capecitabine and oxaliplatin for gastric cancer after D2 gastrectomy (CLASSIC): a phase 3 open-label, randomised controlled trial, Lancet, 379, 315, 10.1016/S0140-6736(11)61873-4

Luo, 2010, Phase II trial of XELOX as first-line treatment for patients with advanced gastric cancer, Chemotherapy, 56, 94, 10.1159/000305256

van Westreenen, 2004, Systematic review of the staging performance of 18F-fluorodeoxyglucose positron emission tomography in esophageal cancer, J Clin Oncol, 22, 3805, 10.1200/JCO.2004.01.083

Bascoul-Mollevi, 2017, Health-related quality of life results from the PRODIGE 5/ACCORD 17 randomised trial of FOLFOX versus fluorouracil-cisplatin regimen in oesophageal cancer, Eur J Cancer, 84, 239, 10.1016/j.ejca.2017.07.038

Kato, 2018, Analysis of circulating tumor DNA and clinical correlates in patients with esophageal, gastroesophageal junction, and gastric adenocarcinoma, Clin Cancer Res, 24, 6248, 10.1158/1078-0432.CCR-18-1128

Bang, 2012, Adjuvant capecitabine and oxaliplatin for gastric cancer after D2 gastrectomy (CLASSIC): a phase 3 open-label, randomised controlled trial, Lancet, 379, 315, 10.1016/S0140-6736(11)61873-4

Sym, 2008, Salvage chemotherapy with biweekly irinotecan, plus 5-fluorouracil and leucovorin in patients with advanced gastric cancer previously treated with fluoropyrimidine, platinum, and taxane, Am J Clin Oncol, 31, 151, 10.1097/COC.0b013e31815878a2

Burtness, 2009, Phase II trial of docetaxel-irinotecan combination in advanced esophageal cancer, Ann Oncol, 20, 1242, 10.1093/annonc/mdn787

Assersohn, 2004, Phase II study of irinotecan and 5-fluorouracil/leucovorin in patients with primary refractory or relapsed advanced oesophageal and gastric carcinoma, Ann Oncol, 15, 64, 10.1093/annonc/mdh007

Urschel, 2003, A meta-analysis of randomized controlled trials that compared neoadjuvant chemoradiation and surgery to surgery alone for resectable esophageal cancer, Am J Surg, 185, 538, 10.1016/S0002-9610(03)00066-7

Dank, 2008, Randomized phase III study comparing irinotecan combined with 5-fluorouracil and folinic acid to cisplatin combined with 5-fluorouracil in chemotherapy naive patients with advanced adenocarcinoma of the stomach or esophagogastric junction, Ann Oncol, 19, 1450, 10.1093/annonc/mdn166

Reichelt, 2007, Frequent homogeneous HER-2 amplification in primary and metastatic adenocarcinoma of the esophagus, Mod Pathol, 20, 120, 10.1038/modpathol.3800712

Herskovic, 1992, Combined chemotherapy and radiotherapy compared with radiotherapy alone in patients with cancer of the esophagus, N Engl J Med, 326, 1593, 10.1056/NEJM199206113262403

Le, 2015, PD-1 blockade in tumors with mismatch-repair deficiency, N Engl J Med, 372, 2509, 10.1056/NEJMoa1500596

Luo, 2010, Phase II trial of XELOX as first-line treatment for patients with advanced gastric cancer, Chemotherapy, 56, 94, 10.1159/000305256

Sudo, 2014, Importance of surveillance and success of salvage strategies after definitive chemoradiation in patients with esophageal cancer, J Clin Oncol, 32, 3400, 10.1200/JCO.2014.56.7156

Cooper, 1999, Chemoradiotherapy of locally advanced esophageal cancer: long-term follow-up of a prospective randomized trial (RTOG 85-01), JAMA, 281, 1623, 10.1001/jama.281.17.1623

Oppedijk, 2014, Patterns of recurrence after surgery alone versus preoperative chemoradiotherapy and surgery in the CROSS trials, J Clin Oncol, 32, 385, 10.1200/JCO.2013.51.2186

Hong, 2004, A phase II trial of capecitabine in previously untreated patients with advanced and/or metastatic gastric cancer, Ann Oncol, 15, 1344, 10.1093/annonc/mdh343

Schoppmann, 2010, Expression of Her-2 in carcinomas of the esophagus, Am J Surg Pathol, 34, 1868, 10.1097/PAS.0b013e3181f8be17

Bang, 2010, Trastuzumab in combination with chemotherapy versus chemotherapy alone for treatment of HER2-positive advanced gastric or gastro-oesophageal junction cancer (ToGA): a phase 3, open-label, randomised controlled trial, Lancet, 376, 687, 10.1016/S0140-6736(10)61121-X

Kato, 2018, Analysis of circulating tumor DNA and clinical correlates in patients with esophageal, gastroesophageal junction, and gastric adenocarcinoma, Clin Cancer Res, 24, 6248, 10.1158/1078-0432.CCR-18-1128

Park, 2008, Capecitabine in combination with oxaliplatin (XELOX) as a first-line therapy for advanced gastric cancer, Cancer Chemother Pharmacol, 61, 623, 10.1007/s00280-007-0515-7

van Hagen, 2012, Preoperative chemoradiotherapy for esophageal or junctional cancer, N Engl J Med, 366, 2074, 10.1056/NEJMoa1112088

Oppedijk, 2014, Patterns of recurrence after surgery alone versus preoperative chemoradiotherapy and surgery in the CROSS trials, J Clin Oncol, 32, 385, 10.1200/JCO.2013.51.2186

Van Cutsem, 2006, Phase III study of docetaxel and cisplatin plus fluorouracil compared with cisplatin and fluorouracil as first-line therapy for advanced gastric cancer: a report of the V325 Study Group, J Clin Oncol, 24, 4991, 10.1200/JCO.2006.06.8429

Bartley, 2017, HER2 testing and clinical decision making in gastroesophageal adenocarcinoma: guideline from the College of American Pathologists, American Society for Clinical Pathology, and the American Society of Clinical Oncology, J Clin Oncol, 35, 446, 10.1200/JCO.2016.69.4836

Rizk, 2010, Optimum lymphadenectomy for esophageal cancer, Ann Surg, 251, 46, 10.1097/SLA.0b013e3181b2f6ee

Lorenzen, 2009, Cetuximab plus cisplatin-5-fluorouracil versus cisplatin-5-fluorouracil alone in first-line metastatic squamous cell carcinoma of the esophagus: a randomized phase II study of the Arbeitsgemeinschaft Internistische Onkologie, Ann Oncol, 20, 1667, 10.1093/annonc/mdp069

Schag, 1984, Karnofsky performance status revisited: reliability, validity, and guidelines, J Clin Oncol, 2, 187, 10.1200/JCO.1984.2.3.187

Peyre, 2008, Predicting systemic disease in patients with esophageal cancer after esophagectomy: a multinational study on the significance of the number of involved lymph nodes, Ann Surg, 248, 979, 10.1097/SLA.0b013e3181904f3c

Herskovic, 1992, Combined chemotherapy and radiotherapy compared with radiotherapy alone in patients with cancer of the esophagus, N Engl J Med, 326, 1593, 10.1056/NEJM199206113262403

Herceptin, 2010, Administration approves trastuzumab Available at http wayback archive it org http www fda gov AboutFDA CentersOffices OfficeofMedicalProductsandTobacco CDER ucm htm Accessed, Food Drug, 21, 7993

Petrasch, 1998, Chemotherapy with cisplatin and paclitaxel in patients with locally advanced, recurrent or metastatic oesophageal cancer, Br J Cancer, 78, 511, 10.1038/bjc.1998.524

Ryan, 2011, Obesity, metabolic syndrome and esophageal adenocarcinoma: epidemiology, etiology and new targets, Cancer Epidemiol, 35, 309, 10.1016/j.canep.2011.03.001

February, 2019, Administration Ramucirumab Available at http wayback archive it org http www fda gov Drugs InformationOnDrugs ApprovedDrugs ucm htm Accessed, Food Drug, 21, 2014

Schag, 1984, Karnofsky performance status revisited: reliability, validity, and guidelines, J Clin Oncol, 2, 187, 10.1200/JCO.1984.2.3.187

de Graaf, 2007, The role of staging laparoscopy in oesophagogastric cancers, Eur J Surg Oncol, 33, 988, 10.1016/j.ejso.2007.01.007

Ohtsu, 2003, Randomized phase III trial of fluorouracil alone versus fluorouracil plus cisplatin versus uracil and tegafur plus mitomycin in patients with unresectable, advanced gastric cancer: the Japan Clinical Oncology Group Study (JCOG9205), J Clin Oncol, 21, 54, 10.1200/JCO.2003.04.130

Elsaid, 2005, Final results of a randomized phase III trial of docetaxel, carboplatin and 5FU versus epirubicin, cisplatin and 5FU for locally advanced gastric cancer, J Clin Oncol, 23, 4014, 10.1200/jco.2005.23.16_suppl.4014

Elsaid, 2005, Final results of a randomized phase III trial of docetaxel, carboplatin and 5FU versus epirubicin, cisplatin and 5FU for locally advanced gastric cancer, J Clin Oncol, 23, 4014, 10.1200/jco.2005.23.16_suppl.4014

Assersohn, 2004, Phase II study of irinotecan and 5-fluorouracil/leucovorin in patients with primary refractory or relapsed advanced oesophageal and gastric carcinoma, Ann Oncol, 15, 64, 10.1093/annonc/mdh007

Shitara, 2018, Trifluridine/tipiracil versus placebo in patients with heavily pretreated metastatic gastric cancer (TAGS): a randomised, double-blind, placebo-controlled, phase 3 trial, Lancet Oncol, 19, 1437, 10.1016/S1470-2045(18)30739-3

Ma, 2018, Comparison of the prognosis of neoadjuvant chemoradiotherapy treatment with surgery alone in esophageal carcinoma: a meta-analysis, OncoTargets Ther, 11, 3441, 10.2147/OTT.S145063

Al-Batran, 2008, Phase III trial in metastatic gastroesophageal adenocarcinoma with fluorouracil, leucovorin plus either oxaliplatin or cisplatin: a study of the Arbeitsgemeinschaft Internistische Onkologie, J Clin Oncol, 26, 1435, 10.1200/JCO.2007.13.9378

Peyre, 2008, Predicting systemic disease in patients with esophageal cancer after esophagectomy: a multinational study on the significance of the number of involved lymph nodes, Ann Surg, 248, 979, 10.1097/SLA.0b013e3181904f3c

Siewert, 1996, Carcinoma of the cardia: carcinoma of the gastroesophageal junction - classification, pathology, and extent of resection, Dis Esophagus, 9, 173

Nath, 2008, Peritoneal lavage cytology in patients with oesophagogastric adenocarcinoma, Br J Surg, 95, 721, 10.1002/bjs.6107

Rüdiger Siewert, 2000, Adenocarcinoma of the esophagogastric junction: results of surgical therapy based on anatomical/topographic classification in 1,002 consecutive patients, Ann Surg, 232, 353, 10.1097/00000658-200009000-00007

Lou, 2013, Esophageal cancer recurrence patterns and implications for surveillance, J Thorac Oncol, 8, 1558, 10.1097/01.JTO.0000437420.38972.fb

Moelans, 2010, Her-2/neu testing and therapy in gastroesophageal adenocarcinoma, Pathol Res Int, 2011, 674182

Dreilich, 2006, HER-2 overexpression (3+) in patients with squamous cell esophageal carcinoma correlates with poorer survival, Dis Esophagus, 19, 224, 10.1111/j.1442-2050.2006.00570.x

Shitara, 2018, Pembrolizumab versus paclitaxel for previously treated, advanced gastric or gastro-oesophageal junction cancer (KEYNOTE-061): a randomised, open-label, controlled, phase 3 trial, Lancet, 392, 123, 10.1016/S0140-6736(18)31257-1

Maugeri-Saccà, 2013, FOLFIRI as a second-line therapy in patients with docetaxel-pretreated gastric cancer: a historical cohort, J Exp Clin Cancer Res, 32, 67, 10.1186/1756-9966-32-67

Rüschoff, 2010, HER2 diagnostics in gastric cancer-guideline validation and development of standardized immunohistochemical testing, Virchows Arch, 457, 299, 10.1007/s00428-010-0952-2

Oken, 1982, Toxicity and response criteria of the Eastern Cooperative Oncology Group, Am J Clin Oncol, 5, 649, 10.1097/00000421-198212000-00014

Sjoquist, 2011, Survival after neoadjuvant chemotherapy or chemoradiotherapy for resectable oesophageal carcinoma: an updated meta-analysis, Lancet Oncol, 12, 681, 10.1016/S1470-2045(11)70142-5

Meerten, 2010, Definitive concurrent chemoradiation (CRT) with weekly paclitaxel and carboplatin for patients (pts) with irresectable esophageal cancer: a phase II study, J Clin Oncol, 28, e14508, 10.1200/jco.2010.28.15_suppl.e14508

Lou, 2013, Esophageal cancer recurrence patterns and implications for surveillance, J Thorac Oncol, 8, 1558, 10.1097/01.JTO.0000437420.38972.fb

Alderson, 2017, Neoadjuvant cisplatin and fluorouracil versus epirubicin, cisplatin, and capecitabine followed by resection in patients with oesophageal adenocarcinoma (UK MRC OE05): an open-label, randomised phase 3 trial, Lancet Oncol, 18, 1249, 10.1016/S1470-2045(17)30447-3

Fuchs, 2019, Ramucirumab with cisplatin and fluoropyrimidine as first-line therapy in patients with metastatic gastric or junctional adenocarcinoma (RAINFALL): a double-blind, randomised, placebo-controlled, phase 3 trial, Lancet Oncol, 20, 420, 10.1016/S1470-2045(18)30791-5

Groth, 2010, Determination of the minimum number of lymph nodes to examine to maximize survival in patients with esophageal carcinoma: data from the Surveillance Epidemiology and End Results database, J Thorac Cardiovasc Surg, 139, 612, 10.1016/j.jtcvs.2009.07.017

Tirumani, 2015, Esophageal carcinoma: current concepts in the role of imaging in staging and management, Can Assoc Radiol J, 66, 130, 10.1016/j.carj.2014.08.006

Moehler, 2010, A randomized multicenter phase II study comparing capecitabine with irinotecan or cisplatin in metastatic adenocarcinoma of the stomach or esophagogastric junction, Ann Oncol, 21, 71, 10.1093/annonc/mdp269

Rice, 2016, Worldwide Esophageal Cancer Collaboration: clinical staging data, Dis Esophagus, 29, 707, 10.1111/dote.12493

Kofoed, 2012, Survival after adjuvant chemoradiotherapy or surgery alone in resectable adenocarcinoma at the gastro-esophageal junction, Scand J Surg, 101, 26, 10.1177/145749691210100106

Moelans, 2010, Her-2/neu testing and therapy in gastroesophageal adenocarcinoma, Pathol Res Int, 2011, 674182

Coccolini, 2018, Neoadjuvant chemotherapy in advanced gastric and esophago-gastric cancer. Meta-analysis of randomized trials, Int J Surg, 51, 120, 10.1016/j.ijsu.2018.01.008

Smalley, 2012, Updated analysis of SWOG-directed intergroup study 0116: a phase III trial of adjuvant radiochemotherapy versus observation after curative gastric cancer resection, J Clin Oncol, 30, 2327, 10.1200/JCO.2011.36.7136

Wolff, 2009, Weekly high-dose 5-fluorouracil as a 24-h infusion and sodium folinic acid (AIO regimen) plus irinotecan in patients with locally advanced nonresectable and metastatic adenocarcinoma or squamous cell carcinoma of the oesophagus: a phase II trial, Anticancer Drugs, 20, 165, 10.1097/CAD.0b013e32831f8ec9

February, 2019, Administration Ramucirumab Available at http wayback archive it org http www fda gov Drugs InformationOnDrugs ApprovedDrugs ucm htm Accessed, Food Drug, 21, 2014

Meerten, 2010, Definitive concurrent chemoradiation (CRT) with weekly paclitaxel and carboplatin for patients (pts) with irresectable esophageal cancer: a phase II study, J Clin Oncol, 28, e14508, 10.1200/jco.2010.28.15_suppl.e14508

Freedman, 2007, A prospective study of tobacco, alcohol, and the risk of esophageal and gastric cancer subtypes, Am J Epidemiol, 165, 1424, 10.1093/aje/kwm051

Ford, 2014, Docetaxel versus active symptom control for refractory oesophagogastric adenocarcinoma (COUGAR-02): an open-label, phase 3 randomised controlled trial, Lancet Oncol, 15, 78, 10.1016/S1470-2045(13)70549-7

Fuchs, 2018, Safety and efficacy of pembrolizumab monotherapy in patients with previously treated advanced gastric and gastroesophageal junction cancer: phase 2 clinical KEYNOTE-059 trial, JAMA Oncol, 4, e180013, 10.1001/jamaoncol.2018.0013

Hechtman, 2012, HER2/neu gene amplification and protein overexpression in gastric and gastroesophageal junction adenocarcinoma: a review of histopathology, diagnostic testing, and clinical implications, Arch Pathol Lab Med, 136, 691, 10.5858/arpa.2011-0168-RS

Hofmann, 2008, Assessment of a HER2 scoring system for gastric cancer: results from a validation study, Histopathology, 52, 797, 10.1111/j.1365-2559.2008.03028.x

Albertsson, 2007, Phase II studies on docetaxel alone every third week, or weekly in combination with gemcitabine in patients with primary locally advanced, metastatic, or recurrent esophageal cancer, Med Oncol, 24, 407, 10.1007/s12032-007-0028-6

Ajani, 2006, Phase II trial of preoperative chemoradiation in patients with localized gastric adenocarcinoma (RTOG 9904): quality of combined modality therapy and pathologic response, J Clin Oncol, 24, 3953, 10.1200/JCO.2006.06.4840

Gadgeel, 2003, Phase II study of paclitaxel and carboplatin in patients with advanced gastric cancer, Am J Clin Oncol, 26, 37, 10.1097/00000421-200302000-00008

van Westreenen, 2004, Systematic review of the staging performance of 18F-fluorodeoxyglucose positron emission tomography in esophageal cancer, J Clin Oncol, 22, 3805, 10.1200/JCO.2004.01.083

BartleyAN, 2018, Template for reporting results of DNA mismatch repair testing in patients being considered for checkpoint inhibitor immunotherapy Illinois College of American Pathologists

Sjoquist, 2011, Survival after neoadjuvant chemotherapy or chemoradiotherapy for resectable oesophageal carcinoma: an updated meta-analysis, Lancet Oncol, 12, 681, 10.1016/S1470-2045(11)70142-5

Rizk, 2010, Optimum lymphadenectomy for esophageal cancer, Ann Surg, 251, 46, 10.1097/SLA.0b013e3181b2f6ee

Okines, 2009, Meta-analysis of the REAL-2 and ML17032 trials: evaluating capecitabine-based combination chemotherapy and infused 5-fluorouracil-based combination chemotherapy for the treatment of advanced oesophago-gastric cancer, Ann Oncol, 20, 1529, 10.1093/annonc/mdp047

Dorth, 2014, Patterns of recurrence after trimodality therapy for esophageal cancer, Cancer, 120, 2099, 10.1002/cncr.28703

Wilke, 2014, Ramucirumab plus paclitaxel versus placebo plus paclitaxel in patients with previously treated advanced gastric or gastro-oesophageal junction adenocarcinoma (RAINBOW): a double-blind, randomised phase 3 trial, Lancet Oncol, 15, 1224, 10.1016/S1470-2045(14)70420-6

Rice, 2016, Worldwide Esophageal Cancer Collaboration: clinical staging data, Dis Esophagus, 29, 707, 10.1111/dote.12493

Schoppmann, 2010, Expression of Her-2 in carcinomas of the esophagus, Am J Surg Pathol, 34, 1868, 10.1097/PAS.0b013e3181f8be17

Thuss-Patience, 2011, Survival advantage for irinotecan versus best supportive care as second-line chemotherapy in gastric cancer--a randomised phase III study of the Arbeitsgemeinschaft Internistische Onkologie (AIO), Eur J Cancer, 47, 2306, 10.1016/j.ejca.2011.06.002

Torre, 2016, Global cancer incidence and mortality rates and trends–an update, Cancer Epidemiol Biomarkers Prev, 25, 16, 10.1158/1055-9965.EPI-15-0578

Dreilich, 2006, HER-2 overexpression (3+) in patients with squamous cell esophageal carcinoma correlates with poorer survival, Dis Esophagus, 19, 224, 10.1111/j.1442-2050.2006.00570.x

Kojima, 2019, Pembrolizumab versus chemotherapy as second-line therapy for advanced esophageal cancer: phase III KEYNOTE-181 study, J Clin Oncol, 37, 2, 10.1200/JCO.2019.37.4_suppl.2

Boonstra, 2011, Chemotherapy followed by surgery versus surgery alone in patients with resectable oesophageal squamous cell carcinoma: long-term results of a randomized controlled trial, BMC Cancer, 11, 181, 10.1186/1471-2407-11-181

Fuchs, 2018, Safety and efficacy of pembrolizumab monotherapy in patients with previously treated advanced gastric and gastroesophageal junction cancer: phase 2 clinical KEYNOTE-059 trial, JAMA Oncol, 4, e180013, 10.1001/jamaoncol.2018.0013

Allum, 2009, Long-term results of a randomized trial of surgery with or without preoperative chemotherapy in esophageal cancer, J Clin Oncol, 27, 5062, 10.1200/JCO.2009.22.2083

Taketa, 2014, Post-chemoradiation surgical pathology stage can customize the surveillance strategy in patients with esophageal adenocarcinoma, J Natl Compr Canc Netw, 12, 1139, 10.6004/jnccn.2014.0111

Janmaat, 2017, Palliative chemotherapy and targeted therapies for esophageal and gastroesophageal junction cancer, Cochrane Database Syst Rev, 11, CD004063

Kojima, 2019, Pembrolizumab versus chemotherapy as second-line therapy for advanced esophageal cancer: phase III KEYNOTE-181 study, J Clin Oncol, 37, 2, 10.1200/JCO.2019.37.4_suppl.2

Wilke, 2014, Ramucirumab plus paclitaxel versus placebo plus paclitaxel in patients with previously treated advanced gastric or gastro-oesophageal junction adenocarcinoma (RAINBOW): a double-blind, randomised phase 3 trial, Lancet Oncol, 15, 1224, 10.1016/S1470-2045(14)70420-6

Bang, 2010, Trastuzumab in combination with chemotherapy versus chemotherapy alone for treatment of HER2-positive advanced gastric or gastro-oesophageal junction cancer (ToGA): a phase 3, open-label, randomised controlled trial, Lancet, 376, 687, 10.1016/S0140-6736(10)61121-X

Day, 2011, Phase I trial of docetaxel, cisplatin and concurrent radical radiotherapy in locally advanced oesophageal cancer, Br J Cancer, 104, 265, 10.1038/sj.bjc.6606051

Blum Murphy, 2018, A phase I/II study of docetaxel, oxaliplatin, and fluorouracil (D-FOX) chemotherapy in patients with untreated locally unresectable or metastatic adenocarcinoma of the stomach and gastroesophageal junction, Am J Clin Oncol, 41, 321, 10.1097/COC.0000000000000271

Minsky, 2002, INT 0123 (Radiation Therapy Oncology Group 94-05) phase III trial of combined-modality therapy for esophageal cancer: high-dose versus standard-dose radiation therapy, J Clin Oncol, 20, 1167, 10.1200/JCO.2002.20.5.1167

Turati, 2013, A meta-analysis of body mass index and esophageal and gastric cardia adenocarcinoma, Ann Oncol, 24, 609, 10.1093/annonc/mds244

Ross, 2002, Prospective randomized trial comparing mitomycin, cisplatin, and protracted venous-infusion fluorouracil (PVI 5-FU) with epirubicin, cisplatin, and PVI 5-FU in advanced esophagogastric cancer, J Clin Oncol, 20, 1996, 10.1200/JCO.2002.08.105

Turati, 2013, A meta-analysis of body mass index and esophageal and gastric cardia adenocarcinoma, Ann Oncol, 24, 609, 10.1093/annonc/mds244

Khushalani, 2002, Oxaliplatin in combination with protracted-infusion fluorouracil and radiation: report of a clinical trial for patients with esophageal cancer, J Clin Oncol, 20, 2844, 10.1200/JCO.2002.12.032

Tanner, 2005, Amplification of HER-2 in gastric carcinoma: association with Topoisomerase IIalpha gene amplification, intestinal type, poor prognosis and sensitivity to trastuzumab, Ann Oncol, 16, 273, 10.1093/annonc/mdi064

Fuchs, 2014, Ramucirumab monotherapy for previously treated advanced gastric or gastro-oesophageal junction adenocarcinoma (REGARD): an international, randomised, multicentre, placebo-controlled, phase 3 trial, Lancet, 383, 31, 10.1016/S0140-6736(13)61719-5

Bang, 2009, Pathological features of advanced gastric cancer (GC): relationship to human epidermal growth factor receptor 2 (HER2) positivity in the global screening programme of the ToGA trial [abstract], J Clin Oncol, 27, Abstract 4556, 10.1200/jco.2009.27.15_suppl.4556

Kang, 2009, Capecitabine/cisplatin versus 5-fluorouracil/cisplatin as first-line therapy in patients with advanced gastric cancer: a randomised phase III noninferiority trial, Ann Oncol, 20, 666, 10.1093/annonc/mdn717

Sudo, 2013, Locoregional failure rate after preoperative chemoradiation of esophageal adenocarcinoma and the outcomes of salvage strategies, J Clin Oncol, 31, 4306, 10.1200/JCO.2013.51.7250

Muro, 2016, Pembrolizumab for patients with PD-L1-positive advanced gastric cancer (KEYNOTE-012): a multicentre, open-label, phase 1b trial, Lancet Oncol, 17, 717, 10.1016/S1470-2045(16)00175-3

Ajani, 1994, Activity of taxol in patients with squamous cell carcinoma and adenocarcinoma of the esophagus, J Natl Cancer Inst, 86, 1086, 10.1093/jnci/86.14.1086

Hofmann, 2008, Assessment of a HER2 scoring system for gastric cancer: results from a validation study, Histopathology, 52, 797, 10.1111/j.1365-2559.2008.03028.x

SwisherSG, 2010, Improved long - term outcome with chemoradiotherapy strategies in esophageal cancer discussion, Ann Thorac Surg, 892, 10.1016/j.athoracsur.2010.04.061

Macdonald, 2001, Chemoradiotherapy after surgery compared with surgery alone for adenocarcinoma of the stomach or gastroesophageal junction, N Engl J Med, 345, 725, 10.1056/NEJMoa010187

Dorth, 2014, Patterns of recurrence after trimodality therapy for esophageal cancer, Cancer, 120, 2099, 10.1002/cncr.28703

Ma, 2018, Comparison of the prognosis of neoadjuvant chemoradiotherapy treatment with surgery alone in esophageal carcinoma: a meta-analysis, OncoTargets Ther, 11, 3441, 10.2147/OTT.S145063

Oken, 1982, Toxicity and response criteria of the Eastern Cooperative Oncology Group, Am J Clin Oncol, 5, 649, 10.1097/00000421-198212000-00014

Noh, 2014, Adjuvant capecitabine plus oxaliplatin for gastric cancer after D2 gastrectomy (CLASSIC): 5-year follow-up of an open-label, randomised phase 3 trial, Lancet Oncol, 15, 1389, 10.1016/S1470-2045(14)70473-5

Thuss-Patience, 2011, Survival advantage for irinotecan versus best supportive care as second-line chemotherapy in gastric cancer--a randomised phase III study of the Arbeitsgemeinschaft Internistische Onkologie (AIO), Eur J Cancer, 47, 2306, 10.1016/j.ejca.2011.06.002

Dank, 2008, Randomized phase III study comparing irinotecan combined with 5-fluorouracil and folinic acid to cisplatin combined with 5-fluorouracil in chemotherapy naive patients with advanced adenocarcinoma of the stomach or esophagogastric junction, Ann Oncol, 19, 1450, 10.1093/annonc/mdn166

Bedenne, 2007, Chemoradiation followed by surgery compared with chemoradiation alone in squamous cancer of the esophagus: FFCD 9102, J Clin Oncol, 25, 1160, 10.1200/JCO.2005.04.7118

Rusch, 2004, Are cancers of the esophagus, gastroesophageal junction, and cardia one disease, two, or several?, Semin Oncol, 31, 444, 10.1053/j.seminoncol.2004.04.023

Allum, 2009, Long-term results of a randomized trial of surgery with or without preoperative chemotherapy in esophageal cancer, J Clin Oncol, 27, 5062, 10.1200/JCO.2009.22.2083

Siewert, 2006, Adenocarcinoma of the esophago-gastric junction, Scand J Surg, 95, 260, 10.1177/145749690609500409

Siewert, 2006, Adenocarcinoma of the esophago-gastric junction, Scand J Surg, 95, 260, 10.1177/145749690609500409

Ychou, 2011, Perioperative chemotherapy compared with surgery alone for resectable gastroesophageal adenocarcinoma: an FNCLCC and FFCD multicenter phase III trial, J Clin Oncol, 29, 1715, 10.1200/JCO.2010.33.0597

Ilson, 2004, Phase II trial of weekly irinotecan/cisplatin in advanced esophageal cancer, Oncology (Williston Park), 18, 22

Le, 2017, Mismatch repair deficiency predicts response of solid tumors to PD-1 blockade, Science, 357, 409, 10.1126/science.aan6733

Munden, 2006, Esophageal cancer: the role of integrated CT-PET in initial staging and response assessment after preoperative therapy, J Thorac Imaging, 21, 137, 10.1097/00005382-200605000-00005

Okines, 2009, Meta-analysis of the REAL-2 and ML17032 trials: evaluating capecitabine-based combination chemotherapy and infused 5-fluorouracil-based combination chemotherapy for the treatment of advanced oesophago-gastric cancer, Ann Oncol, 20, 1529, 10.1093/annonc/mdp047

Torre, 2015, Global cancer statistics, 2012, CA Cancer J Clin, 65, 87, 10.3322/caac.21262

Sumpter, 2005, Report of two protocol planned interim analyses in a randomised multicentre phase III study comparing capecitabine with fluorouracil and oxaliplatin with cisplatin in patients with advanced oesophagogastric cancer receiving ECF, Br J Cancer, 92, 1976, 10.1038/sj.bjc.6602572

Kim, 2010, A multi-center phase II study of docetaxel plus cisplatin as first-line therapy in patients with metastatic squamous cell esophageal cancer, Cancer Chemother Pharmacol, 66, 31, 10.1007/s00280-009-1130-6

Munden, 2006, Esophageal cancer: the role of integrated CT-PET in initial staging and response assessment after preoperative therapy, J Thorac Imaging, 21, 137, 10.1097/00005382-200605000-00005

Le, 2016, PD-1 blockade in mismatch repair deficient non-colorectal gastrointestinal cancers, J Clin Oncol, 34, 195, 10.1200/jco.2016.34.4_suppl.195

Kim, 2009, Multimodality assessment of esophageal cancer: preoperative staging and monitoring of response to therapy, Radiographics, 29, 403, 10.1148/rg.292085106

Leichman, 2011, S0356: a phase II clinical and prospective molecular trial with oxaliplatin, fluorouracil, and external-beam radiation therapy before surgery for patients with esophageal adenocarcinoma, J Clin Oncol, 29, 4555, 10.1200/JCO.2011.36.7490

Kleinberg, 2007, Chemoradiation in the management of esophageal cancer, J Clin Oncol, 25, 4110, 10.1200/JCO.2007.12.0881

Le, 2016, PD-1 blockade in mismatch repair deficient non-colorectal gastrointestinal cancers, J Clin Oncol, 34, 195, 10.1200/jco.2016.34.4_suppl.195

Kato, 2019, KEYNOTE-590: Phase III study of first-line chemotherapy with or without pembrolizumab for advanced esophageal cancer, Future Oncol, 15, 1057, 10.2217/fon-2018-0609

Tepper, 2008, Phase III trial of trimodality therapy with cisplatin, fluorouracil, radiotherapy, and surgery compared with surgery alone for esophageal cancer: CALGB 9781, J Clin Oncol, 26, 1086, 10.1200/JCO.2007.12.9593

Janmaat, 2017, Palliative chemotherapy and targeted therapies for esophageal and gastroesophageal junction cancer, Cochrane Database Syst Rev, 11, CD004063

Ajani, 1994, Activity of taxol in patients with squamous cell carcinoma and adenocarcinoma of the esophagus, J Natl Cancer Inst, 86, 1086, 10.1093/jnci/86.14.1086

Gravalos, 2008, HER2 in gastric cancer: a new prognostic factor and a novel therapeutic target, Ann Oncol, 19, 1523, 10.1093/annonc/mdn169

Tabernero, 2017, Exposure-response analyses of ramucirumab from two randomized, phase III trials of second-line treatment of advanced gastric or gastroesophageal junction cancer, Mol Cancer Ther, 16, 2215, 10.1158/1535-7163.MCT-16-0895

Kim, 2012, A randomized phase II trial of S-1-oxaliplatin versus capecitabine-oxaliplatin in advanced gastric cancer, Eur J Cancer, 48, 518, 10.1016/j.ejca.2011.12.017

Enzinger, 2016, CALGB 80403 (Alliance)/E1206: a randomized phase II study of three chemotherapy regimens plus cetuximab in metastatic esophageal and gastroesophageal junction cancers, J Clin Oncol, 34, 2736, 10.1200/JCO.2015.65.5092

WainbergZA, 2017, KEYNOTE update efficacy and safety of pembrolizumab alone or in combination with chemotherapy in patients with advanced gastric or gastroesophageal cancer suppl, Ann Oncol, 28, 059

Kang, 2009, Capecitabine/cisplatin versus 5-fluorouracil/cisplatin as first-line therapy in patients with advanced gastric cancer: a randomised phase III noninferiority trial, Ann Oncol, 20, 666, 10.1093/annonc/mdn717

Kim, 2010, A multi-center phase II study of docetaxel plus cisplatin as first-line therapy in patients with metastatic squamous cell esophageal cancer, Cancer Chemother Pharmacol, 66, 31, 10.1007/s00280-009-1130-6

Macdonald, 2001, Chemoradiotherapy after surgery compared with surgery alone for adenocarcinoma of the stomach or gastroesophageal junction, N Engl J Med, 345, 725, 10.1056/NEJMoa010187

Khushalani, 2002, Oxaliplatin in combination with protracted-infusion fluorouracil and radiation: report of a clinical trial for patients with esophageal cancer, J Clin Oncol, 20, 2844, 10.1200/JCO.2002.12.032

Moehler, 2010, A randomized multicenter phase II study comparing capecitabine with irinotecan or cisplatin in metastatic adenocarcinoma of the stomach or esophagogastric junction, Ann Oncol, 21, 71, 10.1093/annonc/mdp269

Cooper, 1999, Chemoradiotherapy of locally advanced esophageal cancer: long-term follow-up of a prospective randomized trial (RTOG 85-01), JAMA, 281, 1623, 10.1001/jama.281.17.1623

Reichelt, 2007, Frequent homogeneous HER-2 amplification in primary and metastatic adenocarcinoma of the esophagus, Mod Pathol, 20, 120, 10.1038/modpathol.3800712

Sym, 2008, Salvage chemotherapy with biweekly irinotecan, plus 5-fluorouracil and leucovorin in patients with advanced gastric cancer previously treated with fluoropyrimidine, platinum, and taxane, Am J Clin Oncol, 31, 151, 10.1097/COC.0b013e31815878a2

Burtness, 2009, Phase II trial of docetaxel-irinotecan combination in advanced esophageal cancer, Ann Oncol, 20, 1242, 10.1093/annonc/mdn787

Ilson, 2000, A phase II trial of paclitaxel and cisplatin in patients with advanced carcinoma of the esophagus, Cancer J, 6, 316

Enzinger, 2016, CALGB 80403 (Alliance)/E1206: a randomized phase II study of three chemotherapy regimens plus cetuximab in metastatic esophageal and gastroesophageal junction cancers, J Clin Oncol, 34, 2736, 10.1200/JCO.2015.65.5092

Bartley, 2017, HER2 testing and clinical decision making in gastroesophageal adenocarcinoma: guideline from the College of American Pathologists, American Society for Clinical Pathology, and the American Society of Clinical Oncology, J Clin Oncol, 35, 446, 10.1200/JCO.2016.69.4836

Leichman, 2011, S0356: a phase II clinical and prospective molecular trial with oxaliplatin, fluorouracil, and external-beam radiation therapy before surgery for patients with esophageal adenocarcinoma, J Clin Oncol, 29, 4555, 10.1200/JCO.2011.36.7490

Day, 2011, Phase I trial of docetaxel, cisplatin and concurrent radical radiotherapy in locally advanced oesophageal cancer, Br J Cancer, 104, 265, 10.1038/sj.bjc.6606051

Al-Batran, 2017, Management of locally advanced gastroesophageal cancer: still a multidisciplinary global challenge?, Hematol Oncol Clin North Am, 31, 441, 10.1016/j.hoc.2017.01.004

Gadgeel, 2003, Phase II study of paclitaxel and carboplatin in patients with advanced gastric cancer, Am J Clin Oncol, 26, 37, 10.1097/00000421-200302000-00008

Siewert, 1996, Carcinoma of the cardia: carcinoma of the gastroesophageal junction - classification, pathology, and extent of resection, Dis Esophagus, 9, 173

Hechtman, 2012, HER2/neu gene amplification and protein overexpression in gastric and gastroesophageal junction adenocarcinoma: a review of histopathology, diagnostic testing, and clinical implications, Arch Pathol Lab Med, 136, 691, 10.5858/arpa.2011-0168-RS

Zhao, 2018, Neoadjuvant chemotherapy versus neoadjuvant chemoradiotherapy for cancer of the esophagus or the gastroesophageal junction: A meta-analysis based on clinical trials, PLoS One, 13, e0202185, 10.1371/journal.pone.0202185

Engel, 2003, Population attributable risks of esophageal and gastric cancers, J Natl Cancer Inst, 95, 1404, 10.1093/jnci/djg047

SwisherSG, 2010, Improved long - term outcome with chemoradiotherapy strategies in esophageal cancer discussion, Ann Thorac Surg, 892, 10.1016/j.athoracsur.2010.04.061

Bedenne, 2007, Chemoradiation followed by surgery compared with chemoradiation alone in squamous cancer of the esophagus: FFCD 9102, J Clin Oncol, 25, 1160, 10.1200/JCO.2005.04.7118

Le, 2015, PD-1 blockade in tumors with mismatch-repair deficiency, N Engl J Med, 372, 2509, 10.1056/NEJMoa1500596

Blum Murphy, 2018, A phase I/II study of docetaxel, oxaliplatin, and fluorouracil (D-FOX) chemotherapy in patients with untreated locally unresectable or metastatic adenocarcinoma of the stomach and gastroesophageal junction, Am J Clin Oncol, 41, 321, 10.1097/COC.0000000000000271

Lagergren, 2000, The role of tobacco, snuff and alcohol use in the aetiology of cancer of the oesophagus and gastric cardia, Int J Cancer, 85, 340, 10.1002/(SICI)1097-0215(20000201)85:3<340::AID-IJC8>3.0.CO;2-N

Van Cutsem, 2015, Docetaxel plus oxaliplatin with or without fluorouracil or capecitabine in metastatic or locally recurrent gastric cancer: a randomized phase II study, Ann Oncol, 26, 149, 10.1093/annonc/mdu496

Shapiro, 2015, Neoadjuvant chemoradiotherapy plus surgery versus surgery alone for oesophageal or junctional cancer (CROSS): long-term results of a randomised controlled trial, Lancet Oncol, 16, 1090, 10.1016/S1470-2045(15)00040-6

Shah, 2015, Randomized multicenter phase II study of modified docetaxel, cisplatin, and fluorouracil (DCF) versus DCF plus growth factor support in patients with metastatic gastric adenocarcinoma: a study of the US Gastric Cancer Consortium, J Clin Oncol, 33, 3874, 10.1200/JCO.2015.60.7465

Bang, 2017, KEYNOTE-059 cohort 2: safety and efficacy of pembrolizumab (pembro) plus 5-fluorouracil (5-FU) and cisplatin for first-line (1L) treatment of advanced gastric cancer, J Clin Oncol, 35, 4012, 10.1200/JCO.2017.35.15_suppl.4012

Rice, 2017, Cancer of the esophagus and esophagogastric junction-major changes in the American Joint Committee on Cancer eighth edition cancer staging manual, CA Cancer J Clin, 67, 304

Ilson, 2007, Paclitaxel given by a weekly 1-h infusion in advanced esophageal cancer, Ann Oncol, 18, 898, 10.1093/annonc/mdm004

Ychou, 2011, Perioperative chemotherapy compared with surgery alone for resectable gastroesophageal adenocarcinoma: an FNCLCC and FFCD multicenter phase III trial, J Clin Oncol, 29, 1715, 10.1200/JCO.2010.33.0597

WainbergZA, 2017, KEYNOTE update efficacy and safety of pembrolizumab alone or in combination with chemotherapy in patients with advanced gastric or gastroesophageal cancer suppl, Ann Oncol, 28, 059

Van Cutsem, 2006, Phase III study of docetaxel and cisplatin plus fluorouracil compared with cisplatin and fluorouracil as first-line therapy for advanced gastric cancer: a report of the V325 Study Group, J Clin Oncol, 24, 4991, 10.1200/JCO.2006.06.8429